|
1
|
Zhang YZ, Chen X, Fan XX, He JX, Huang J,
Xiao DK, Zhou YL, Zheng SY, Xu JH, Yao XJ, et al: Compound library
screening identified cardiac glycoside digitoxin as an effective
growth inhibitor of gefitinib-resistant non-small cell lung cancer
via downregulation of α-tubulin and inhibition of microtubule
formation. Molecules. 21:3742016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zheng H, Wang M, Wu J, Wang ZM, Nan HJ and
Sun H: Inhibition of mTOR enhances radiosensitivity of lung cancer
cells and protects normal lung cells against radiation. Biochem
Cell Biol. 94:213–220. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Trinidad López C, Bayarri Souto M, Pernas
Oca R, Sánchez-Gracián Delgado C, Vázquez González M, Liste
Vaamonde A, De La Fuente Tardáguila G and De La Fuente Aguado J:
Characteristics of computed tomography perfusion parameters in
non-small-cell-lung-cancer and its relationship to histology, size,
stage an treatment response. Clin Imaging. 50:5–12. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wei H, Su M, Lin R, Li H and Zou C:
Prognostic factors analysis in EGFR mutation-positive non-small
cell lung cancer with brain metastases treated with whole
brain-radiotherapy and EGFR-tyrosine kinase inhibitors. Oncol Lett.
11:2249–2254. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhao T, Gao Z, Wu W, He W and Yang YI:
Effect of synchronous solitary bone metastasectomy and lung cancer
resection on non-small cell lung cancer patients. Oncol Lett.
11:2266–2270. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee P, Leung CC, Restrepo MI, Takahashi K,
Song Y and Porcel JM: Year in review 2015: Lung cancer, pleural
diseases, respiratory infections, bronchiectasis and tuberculosis,
bronchoscopic intervention and imaging. Respirology. 21:961–967.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Matsumoto M, Nakajima W, Seike M, Gemma A
and Tanaka N: Cisplatin-induced apoptosis in non-small-cell lung
cancer cells is dependent on Bax- and Bak-induction pathway and
synergistically activated by BH3-mimetic ABT-263 in p53 wild-type
and mutant cells. Biochem Biophys Res Commun. 473:490–496. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rocco G, Nason K, Brunelli A, Varela G,
Waddell T and Jones DR: Management of stage IIIA (N2) non-small
cell lung cancer: A transatlantic perspective. J Thorac Cardiovasc
Surg. 151:1235–1238. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Parrillo L, Costa V, Raciti GA, Longo M,
Spinelli R, Esposito R, Nigro C, Vastolo V, Desiderio A, Zatterale
F, et al: Hoxa5 undergoes dynamic DNA methylation and
transcriptional repression in the adipose tissue of mice exposed to
high-fat diet. Int J Obes (Lond). 40:929–937. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Morgan R and El-Tanani M: Hox genes as
potential markers of circulating tumour cells. Curr Mol Med.
16:322–327. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sandberg ES, Calikoglu AS, Loechner KJ and
Snyder LL: Short stature homeobox-containing haploinsufficiency in
seven siblings with short stature. Case Rep Endocrinol.
2017:72873512017.PubMed/NCBI
|
|
12
|
Catela C, Shin MM, Lee DH, Liu JP and
Dasen JS: Hox proteins coordinate motor neuron differentiation and
connectivity programs through ret/gfralpha genes. Cell Rep.
14:1901–1915. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Krumlauf R: Hox genes and the hindbrain: A
study in segments. Curr Top Dev Biol. 116:581–596. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhong Z, Shan M, Wang J, Liu T, Xia B, Niu
M, Ren Y and Pang D: HOXD13 methylation status is a prognostic
indicator in breast cancer. Int J Clin Exp Pathol. 8:10716–10724.
2015.PubMed/NCBI
|
|
15
|
Aquino G, Franco R, Sabatino R, Mantia EL,
Scognamiglio G, Collina F, Longo F, Ionna F, Losito NS, Liguori G,
et al: Deregulation of paralogous 13 HOX genes in oral squamous
cell carcinoma. Am J Cancer Res. 5:3042–3055. 2015.PubMed/NCBI
|
|
16
|
DiCicco-Bloom E, Lord C, Zwaigenbaum L,
Courchesne E, Dager SR, Schmitz C, Schultz RT, Crawley J and Young
LJ: The developmental neurobiology of aut-ism spectrum disorder. J
Neurosci. 26:6897–6906. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ranzi AD, da Silva JN, Graziottin TM,
Annels N and Bica CG: Immunohistochemistry biomarkers in nonmuscle
invasive bladder cancer. Appl Immunohistochem Mol Morphol.
25:178–183. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
McGrath SE, Michael A, Morgan R and Pandha
H: EN2 in prostate cancer. Adv Clin Chem. 71:47–76. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kaur H, Sehgal IS, Bal A, Gupta N, Behera
D, Das A and Singh N: Evolving epidemiology of lung cancer in
India: Reducing non-small cell lung cancer-not otherwise specified
and quantifying tobacco smoke exposure are the key. Indian J
Cancer. 54:285–290. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cepollaro S, Della Bella E, de Biase D,
Visani M and Fini M: Evaluation of RNA from human trabecular bone
and identification of stable reference genes. J Cell Physiol.
233:4401–4407. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-(Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Omi M, Harada H, Watanabe Y, Funahashi J
and Nakamura H: Role of En2 in the tectal laminar formation of
chick embryos. Development. 141:2131–2138. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Martin NL, Saba-El-Leil MK, Sadekova S,
Meloche S and Sauvageau G: EN2 is a candidate oncogene in human
breast cancer. Oncogene. 24:6890–6901. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bose SK, Bullard RS and Donald CD:
Oncogenic role of engrailed-2 (en-2) in prostate cancer cell growth
and survival. Transl Oncogenomics. 3:37–43. 2008.PubMed/NCBI
|
|
25
|
Morgan R, Bryan RT, Javed S, Launchbury F,
Zeegers MP, Cheng KK, James ND, Wallace DM, Hurst CD, Ward DG, et
al: Expression of Engrailed-2 (EN2) protein in bladder cancer and
its potential utility as a urinary diagnostic biomarker. Eur J
Cancer. 49:2214–2222. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lai CY, Pan B, Luo Y, Liang WB, Chen J, Ye
DM, Guo JN, Li L and Su ZX: Engrailed-2 is down-regulated but also
ectopically expressed in clear cell renal cell carcinoma. Mol Biol
Rep. 41:3651–3657. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xu W, Banerji S, Davie JR, Kassie F, Yee D
and Kratzke R: Yin yang gene expression ratio signature for lung
cancer prognosis. PLoS One. 8:e687422013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Togel L, Nightingale R, Chueh AC,
Jayachandran A, Tran H, Phesse T, Wu R, Sieber OM, Arango D,
Dhillon AS, et al: Dual targeting of bromodomain and extra-terminal
domain proteins, and WNT or MAPK signaling, inhibits c-MYC
expression and proliferation of colorectal cancer cells. Mol Cancer
Ther. 15:1217–1226. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sempou E, Biasini E, Pinzon-Olejua A,
Harris DA and Malaga-Trillo E: Activation of zebrafish Src family
kinases by the prion protein is an amyloid-β-sensitive signal that
prevents the endocytosis and degradation of E-cadherin/β-catenin
complexes in vivo. Mol Neurodegener. 11:182016. View Article : Google Scholar : PubMed/NCBI
|
